[1] National Center for AIDS/STD Control and Prevention. National HIV/AIDS and STI epidemic situation in December 2023. Chin J AIDS STD 2024;30(3):225. https://doi.org/10.13419/j.cnki.aids.2024.03.01. (In Chinese)
[2] Wang LL, Hong H, Zhang YR, Shi HB, Chen L, Jiang HB, et al. Cost-effectiveness prediction of AIDS interventions among men who have sex with men in Ningbo. Chin J Epidemiol 2022;43(12):2008 − 14. https://doi.org/10.3760/cma.j.cn112338-20220410-00275CrossRef
[3] National Natural Science Foundation of China. Model study of intensive HIV containment strategies in MSM-an integrated cost-effectiveness analysis based on a natural cohort. https://kd.nsfc.cn/finalDetails?id=c1fd2cd1f15c64f5bd443aec560eba34. [2024-7-31].
[4] Garcia-Cremades M, Vučićević K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, et al. Characterizing HIV-preventive, plasma Tenofovir concentrations-a pooled participant-level data analysis from human immunodeficiency virus preexposure prophylaxis clinical trials. Clin Infect Dis 2022;75(11):1873 − 82. https://doi.org/10.1093/cid/ciac313CrossRef
[5] Hodges-Mameletzis I, Dalal S, Msimanga-Radebe B, Rodolph M, Baggaley R. Going global: the adoption of the World Health Organization’s enabling recommendation on oral pre-exposure prophylaxis for HIV. Sex Health 2018;15(6):489 − 500. https://doi.org/10.1071/SH18125CrossRef
[6] Acqired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition). Chin J Infect Dis 2024;42(5):257-84. https://doi.org/10.3760/cma.j.cn311365-20240328-00081. (In Chinese). 
[7] He N. New progress of AIDS epidemiology in China. Chin J Dis Control Prev 2021;25(12):1365 − 8,1480. https://doi.org/10.16462/j.cnki.zhjbkz.2021.12.001CrossRef
[8] Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther 2020;37(5):1778 − 811. https://doi.org/10.1007/s12325-020-01295-0CrossRef
[9] Cui Z, Huang HJ, Zhang TT, Yu ZY, Zhang HL, Yao TT, et al. Low awareness of and willingness to use PrEP in the Chinese YMSM: an alert in YMSM HIV prevention. HIV Med 2021;22(3):185 − 93. https://doi.org/10.1111/hiv.12990CrossRef
[10] Ballreich J, Levengood T, Conti RM. Opportunities and challenges of generic pre-exposure prophylaxis drugs for HIV. J Law Med Ethics 2022;50(S1):32 − 9. https://doi.org/10.1017/jme.2022.33CrossRef
[11] Zhang LK, Wang H. Expert consensus on HIV pre-exposure prophylaxis in China (2023 edition). Chin J AIDS STD 2023;29(9):954-61. https://doi.org/10.13419/j.cnki.aids.2023.09.02. (In Chinese).